Kailera Therapeutics, Inc.(KLRA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 2 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
KLRA Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Kailera Therapeutics, Inc. (KLRA), a Healthcare sector company. KLRA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 2 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q1 2026), Kailera Therapeutics, Inc. reports net income of $-78.9M, free cash flow of $-68.3M. KLRA trades on the Nasdaq exchange and files with the SEC under CIK 2096997. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KLRA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Kailera Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-78.9M
Free Cash Flow
Q1 2026
$-68.3M
AI Insight: KLRA Ratio Trends
Kailera is pre-revenue or in heavy R&D spend phase with -50.5% ROA in Q1 2026, making profitability metrics uninformative.
• ROA of -50.5% in Q1 2026 reflects negative operating income; company appears to be in clinical/development stage with no meaningful earnings.
⚠ All leverage and profitability ratios missing or negative; unable to assess margin trends, cash generation, or balance sheet health from available data.
Get alerted when KLRA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Kailera Therapeutics, Inc. including:
Top Institutional Holders of KLRA
Harbour Capital Advisors, LLC
$342.7K16,570 shTEMA ETFS LLC
$309.3K14,039 sh
| Fund | Value | Shares |
|---|---|---|
| Harbour Capital Advisors, LLC | $342.7K | 16,570 |
| TEMA ETFS LLC | $309.3K | 14,039 |
More Healthcare Companies
View all Healthcare →Put KLRA on your watchlist
Track score changes the day Kailera Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is KLRA a good stock to buy?
13F Pro's AI-powered analysis of Kailera Therapeutics, Inc. (KLRA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KLRA are available on the KLRA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own KLRA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KLRA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Kailera Therapeutics, Inc.'s investment landscape.